Melphalan Macure

Melphalan, the active ingredient in Melphalan Macure, is an alkylating agent presented as an injectable solution for intravenous use. It is employed in the treatment of certain cancers, including multiple myeloma, ovarian cancer, and melanoma, in adult patients.

GNH USA supplies Melphalan Macure as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is an alkylating chemotherapy used in several solid‑tumor and hematologic malignancies. - Multiple myeloma: helps achieve disease control and prolong survival. - Ovarian cancer: used as part of combination regimens to reduce tumor burden. - Melanoma: administered in advanced disease to inhibit tumor growth.

Melphalan can cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Myelosuppression: reduced white blood cells, red blood cells, and platelets. - Fatigue: generalized tiredness during treatment cycles. - Alopecia: temporary hair loss. - Mucositis: inflammation of the mouth lining. - Diarrhea: loose stools or increased frequency.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers later. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: acute kidney injury in susceptible patients.

Melphalan requires careful monitoring and specific safety measures before, during, and after administration. - Baseline labs: obtain complete blood count and renal function before each cycle. - Infection risk: monitor for fever or signs of infection and treat promptly. - Pregnancy: avoid use in pregnant women; discuss contraception with patients of child‑bearing potential. - Drug compatibility: verify compatibility with diluents and infusion sets. - Handling: use aseptic technique and wear protective gloves during preparation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Melphalan may interact with other agents that affect bone‑marrow function or drug metabolism.

Major Interactions (Avoid): - Other alkylating agents: additive myelosuppression. - High‑dose radiation therapy: increased risk of severe tissue damage.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may increase melphalan plasma levels. - Allopurinol: can enhance hematologic toxicity. - Live vaccines: reduced efficacy and potential infection risk.